SPPL2b activators belong to a distinct chemical class that primarily interacts with the SPPL2b enzyme, influencing its activity in various biological processes. SPPL2b, or Signal Peptide Peptidase-Like 2b, is a transmembrane aspartyl protease found predominantly in cellular membranes, especially within the endoplasmic reticulum and Golgi apparatus. This enzyme plays a pivotal role in the regulation of immune responses, particularly in the context of antigen presentation and immune cell activation. SPPL2b activators are a class of molecules that modulate the enzymatic activity of SPPL2b, impacting its substrate processing capabilities and consequently influencing the immune system's functioning.
The exact mechanisms of SPPL2b activators are still a subject of ongoing research, but it is well-established that they can have profound effects on the generation of peptide antigens for presentation by major histocompatibility complex (MHC) molecules. This process is crucial for the immune system's ability to recognize and respond to pathogens and abnormal cells. By targeting SPPL2b, activators can alter the cleavage and release of specific protein fragments, which in turn can affect the repertoire of antigens presented to immune cells. Understanding and manipulating the activity of SPPL2b and its activators have the to provide valuable insights into the immune system's functioning and may have implications in various fields, such as immunology and vaccine development.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $83.00 | 5 | |
Leflunomide can indirectly increasing SPPL2B by modulating immune responses, potentially affecting the proteolytic activities of SPPL2B in immune cells. | ||||||
A77 1726 | 163451-81-8 | sc-207235 | 10 mg | $80.00 | 14 | |
Teriflunomide is an active metabolite of leflunomide and may activate SPPL2B indirectly through its immunosuppressive actions. | ||||||
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $67.00 $284.00 | 6 | |
Imiquimod is an immune response modifier may activate SPPL2B indirectly by stimulating immune cells, leading to changes in protein processing. | ||||||
Filgotinib | 1206161-97-8 | sc-507393 | 10 mg | $150.00 | ||
Filgotinib is another JAK inhibitor with potential immunosuppressive properties. It may increase SPPL2B indirectly through modulation of the immune response. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib is also a JAK inhibitor thatcan indirectly possibly activate SPPL2B by modulating immune cell signaling. | ||||||